Weight Loss Injections After Pregnancy: What the Evidence Actually Says

You've stopped breastfeeding, so when can treatment actually begin?

Picture this: your youngest is eight months old, you finished breastfeeding a couple of months ago, and your GP has mentioned that your BMI is still in a range that carries health risks. You've read about Mounjaro and Wegovy, and you want to know whether you're too early, too late, or right on time to start.

There is no single mandated waiting period written into the UK product licences specifically for the postpartum phase beyond the breastfeeding prohibition itself. What the guidance says is that once breastfeeding has fully ended, eligibility returns to the standard adult criteria: a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, raised cholesterol or prediabetes. The prescriber's job, at that point, is to assess your full picture, not just a number on a scale, but your recovery, any ongoing hormonal considerations, your contraception, and your general health since delivery.

The licensed weight loss injections available in the UK operate as once-weekly subcutaneous injections. Mounjaro (tirzepatide) starts at 2.5mg and is titrated upward by the prescriber. Wegovy (semaglutide) follows its own graduated schedule. Both are prescription-only medicines, which means a qualified clinician must decide suitability, the criteria on a website are a guide, not a green light. If you want to understand what the consultation process looks like, the team at nume describes how that clinical review works in practice.

Worth knowing: postpartum weight retention varies considerably from person to person. Some of it resolves in the first year without medical intervention; some becomes persistent, particularly in the context of sleep disruption, hormonal changes and reduced activity. A prescriber familiar with the postpartum picture will factor this in.

Why breastfeeding is a firm line, not a grey area

Both Mounjaro and Wegovy carry an explicit recommendation against use during breastfeeding. It is not a cautious hedge, it reflects a genuine gap in safety data. Animal studies with GLP-1 medicines have shown excretion into breast milk, and the potential effects on a nursing infant are unknown. The absence of human evidence is itself the reason for caution: we don't have data to say it's safe, which in regulatory terms means it isn't cleared.

The NHS guidance on weight management injections confirms this position clearly, and it is echoed in the Summary of Product Characteristics for both medicines. If you started treatment before discovering you were pregnant and continued into the postpartum period, speak to your doctor before making any decision, this isn't a situation to navigate alone.

The same logic applies if you are planning another pregnancy. Clinical guidance from the MHRA advises using effective contraception during treatment and for a wash-out period before trying to conceive. For tirzepatide specifically, oral contraceptives may be absorbed less reliably, particularly in the early weeks of treatment and after each dose increase, more detail on contraception during treatment covers exactly what the guidance recommends and why. The short version: a non-oral method (condoms, for example) should run alongside the pill for the first four weeks of treatment and for four weeks after any dose step-up. The NHS England guidance on weight management injections sets this out explicitly, and it is the kind of practical point a prescriber will walk through with you at consultation.

What the evidence says about effectiveness after pregnancy, and what it doesn't

The major clinical trials for tirzepatide and semaglutide were not designed specifically around the postpartum population. SURMOUNT-1, the landmark tirzepatide trial published in the New England Journal of Medicine, enrolled thousands of adults with obesity across a broad range of backgrounds, but it was not a postpartum-specific study. The headline figure of around 20% average body-weight reduction at the highest dose tells you something meaningful about the medicine's effect in adults with obesity, but it does not tell you specifically what to expect in the months following delivery.

What can reasonably be inferred is that the biological mechanisms (reduced appetite, slower gastric emptying, altered satiety signalling) operate the same way regardless of how the excess weight was gained. But postpartum physiology is not identical to general obesity; hormonal fluctuations, thyroid changes and the demands of new parenthood all sit alongside any treatment. A prescriber with experience in this area will weigh all of that, not just the trial data.

If you're curious about realistic outcomes from weight loss injections more broadly, the before and after evidence page explains what the trials actually measured and what the numbers mean in practice. And if long-term maintenance is on your mind (as it often is for people who have experienced postpartum weight retention before) there is a specific page on whether weight returns after stopping that addresses that question directly.

The conversation worth having before you start

The most useful thing this page can do is point you toward the right people, not replace them. A prescriber, your GP, or a specialist in weight management can review your full postpartum history, your current health, your contraception and your goals together. That conversation is where suitability is decided, not by a BMI calculator on its own.

If you're not sure whether you meet the eligibility criteria yet, the consultation page sets out exactly what the assessment involves. It is free, it is reviewed the same day by a real clinician at a GPhC-registered pharmacy, and there is no obligation to proceed. For anyone weighing up injections against other options, a comparison of injections and surgical routes may also be useful context. You can also review the general FAQs or get in touch directly if you have a question that is specific to your situation. Suspected side effects from any GLP-1 medicine can be reported to the MHRA via the Yellow Card scheme.